These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17234355)
1. Is lipid lowering treatment aiming for very low LDL levels safe in terms of the synthesis of steroid hormones? Kanat M; Sipahioglu M; Arinc H; Serin E; Yildiz O; Tunckale A; Celebi H Med Hypotheses; 2007; 69(1):104-12. PubMed ID: 17234355 [TBL] [Abstract][Full Text] [Related]
2. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative. Coodley GO; Jorgensen M; Kirschenbaum J; Sparks C; Zeigler L; Albertson BD Am J Med; 2008 Jul; 121(7):604-10. PubMed ID: 18538295 [TBL] [Abstract][Full Text] [Related]
3. In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis? Stegmayr B; Lalau JD; Johnson O Transfus Apher Sci; 2004 Jun; 30(3):213-20. PubMed ID: 15172626 [TBL] [Abstract][Full Text] [Related]
4. Differences between clinical trial efficacy and real-world effectiveness. Davidson MH Am J Manag Care; 2006 Nov; 12(15 Suppl):S405-11. PubMed ID: 17112328 [TBL] [Abstract][Full Text] [Related]
5. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967 [TBL] [Abstract][Full Text] [Related]
6. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548 [TBL] [Abstract][Full Text] [Related]
7. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed? Sarawate CA; Cziraky MJ; Stanek EJ; Willey VJ; Corbelli JC; Charland SL Clin Ther; 2007 Jan; 29(1):196-209. PubMed ID: 17379061 [TBL] [Abstract][Full Text] [Related]
15. Serum lipid profile on admission for ischemic stroke: failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. Smith EE; Abdullah AR; Amirfarzan H; Schwamm LH Neurology; 2007 Feb; 68(9):660-5. PubMed ID: 17325272 [TBL] [Abstract][Full Text] [Related]
16. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H; Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314 [TBL] [Abstract][Full Text] [Related]
18. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
19. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
20. Cholesterol and coronary events. The current thinking. Jones PH Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]